 |
| A newsletter from our Technology, Media & Communications Group on issues relating to the pharmaceutical and bio sciences industry. | 
|
DLA Piper's Pharmaceutical and Bioscience Group
The pharmaceutical and bioscience industries are highly regulated and can present many legal hurdles. DLA Piper has set out to construct a leading team of industry experts. The results (a combination of our international merger and targeted recruitment) has produced one of the finest pharmaceutical and biosciences teams in the world. Our team understands the drivers which affect pharma and biotech lifecycles and marketing strategies, the research and development which goes into the discovery of novel products and their formulation, their subsequent licensing, distribution and other exploitation, as well as the patent enforcement strategies which complement them. We also understand the competitive/dynamics which drive the generic pharmaceuticals industry.
|
|
New joiners
We have recently been joined by two new partners in our Copenhagen office. Anders Valentin and Ole Damsbo are leading Danish patent lawyers. Both Anders and Ole have significant experience and expertise in handling patent litigation, licensing and regulatory matters for pharmaceutical and bioscience clients. Most recently Anders and Ole have been involved in the ongoing battles over generic Omperazol and Atorva-statin. Their contact details are [email protected] and [email protected].
|
|
Patent litigation wall chart
Our Patent Litigation Across Europe wall chart was revised and reissued in 2005. If you have not received a copy and would like to receive one please e-mail [email protected] and a copy will be posted to you.
|
|
Convergence is a monthly e-newsletter produced by members of our TMC group. Each edition focuses on a different industry within the TMC sector. Editions include: Film & Television, IT and Telecoms, Intellectual Property, Publishing & New Media, Pharmaceuticals & Biosciences, Sport. We also produce a Bi-Annual TMC Review. To subscribe to any of these editions please select from the drop down menu in the right hand panel.
For more information please email: [email protected]
If you have been sent this email from a colleague and would like to be added to the mailing list for any of our publications, please send an email to [email protected] stating which publications you would like to receive, along with your name, job title, address and email address. | |
|
|
 |
We may supply your personal data to other member of the DLA Piper Rudnick Gray Cary global organisation (which may be situated outside the European Economic Area ("EEA")) so that we or they may contact you with information about legal services and events offered by us or them subject to your consent,
It is our policy not to pass any of your personal data outside of the DLA Piper Rudnick Gray Cary global organisation or use your personal data for any purposes other than those indicated above.
If you wish to unsubscribe from all TMC related e-bulletins, please tick the unsubscribe button above. If you would like to unsubscribe to the Pharmaceutical and Bio Sciences e-newsletter only please click here. Alternatively, if you no longer wish to receive any information electronically from DLA Piper Rudnick Gray Cary UK LLP and/or any of the DLA Piper Rudnick Gray Cary members, please click here.
Regulated by the Law Society.
DLA Piper Rudnick Gray Cary UK LLP and DLA Piper Rudnick Gray Cary Scotland LLP are part of DLA Piper Rudnick Gray Cary, a global legal services organisation, the members of which are separate and distinct legal entities. For further information please refer to www.dlapiper.com/structure
A list of offices across Asia, Europe and the US can be found at www.dlapiper.com
UK switchboard +44 (0) 8700 111 111
